Light-based technologies are moving from isolated dental procedures toward integrated diagnostic, therapeutic, and regenerative strategies in oral healthcare, according to a comprehensive narrative review published in Frontiers in Oral Health. The review, authored by R. J. Bensadoun, K. Lairedj, and B. R. Carlotti, argues that the central obstacle to wider clinical adoption is not a lack of biological plausibility but a failure of dosimetry: the energy a device emits at its tip is often a poor predictor of the energy that actually reaches the target tissue deep inside the mouth.
The most clinically developed branch of this field is photobiomodulation, or PBM, historically known as low-level laser therapy. PBM uses non-ionizing radiation in the visible red and near-infrared spectrum to trigger nonthermal biological responses. The proposed mechanisms involve mitochondrial metabolism, redox signaling, nitric oxide release, intracellular calcium modulation, transcriptional regulation, and tissue repair. Cytochrome-c oxidase has historically been considered the primary photoacceptor for red and near-infrared light, linking photon absorption to cellular respiration, although contemporary models also emphasize transient changes in reactive oxygen species, membrane channels, and immunometabolic pathways.
The strongest quantitative evidence for PBM in oral medicine comes from cancer therapy-induced oral mucositis, which the review describes as the benchmark indication. Severe mucositis brings intense pain, ulceration, impaired nutrition, dysphagia, opioid dependence, secondary infections, prolonged hospitalizations, and interruptions to anticancer treatment. A 2026 systematic review by Pedroso and colleagues, covering 30 randomized controlled trials with 1,748 patients with head and neck cancer, found that prophylactic PBM substantially reduced the incidence of severe grade 3 to 4 oral mucositis, with relative risks typically ranging from 0.30 to 0.50 compared with placebo or sham controls. Patient-reported pain scores on visual analog scales fell by 2.0 to 3.0 points, effects that correlated with reduced opioid consumption, improved quality of life, and fewer radiation therapy interruptions.
That evidence base is strong enough that two international bodies, the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology and the World Association for Laser Therapy, have issued parameter-specific clinical practice guidelines recommending PBM to prevent oral mucositis in hematopoietic stem cell transplantation patients and in head and neck cancer patients receiving radiotherapy or chemoradiotherapy. The review is careful to note, however, that mechanistic plausibility cannot substitute for indication-specific clinical evidence, and that the maturity of the mucositis data is not matched elsewhere.
Outside supportive oncology, the picture is far more heterogeneous. The review surveys applications in salivary dysfunction, periodontal therapy, oral surgery, temporomandibular disorders, implant osseointegration, orthodontics, and inflammatory mucosal conditions such as recurrent aphthous stomatitis, burning mouth syndrome, and oral lichen planus. In periodontal disease, adjunctive PBM delivered transgingivally or via fiber-optic tips inside the pocket has shown improvements in clinical attachment levels and probing pocket depth when combined with mechanical debridement, but with extreme parameter heterogeneity across studies. For temporomandibular disorders, point-contact treatment over the joint capsule or muscle trigger points has produced clinically relevant pain reductions and improved maximal jaw opening, though diagnostic confusion between muscular and articular pathology complicates interpretation.
Oral surgery recovery and implant dentistry illustrate the same pattern. Surface illumination over extraction sockets has been associated with reductions in postoperative edema, trismus, and acute pain after third molar extractions, but the timing of application relative to the phases of wound healing is poorly standardized. In implant dentistry, trans-osteal or transmucosal illumination has shown promising increases in implant stability quotients and accelerated early bone healing, yet findings are highly inconsistent, in part because cortical bone thickness varies enormously between patients and dramatically changes beam attenuation. Orthodontic applications aimed at accelerating tooth movement suffer from drastically varying wavelengths and exposure schedules and high dependence on individual biological response.
Importantly, the review does not present PBM as universally effective. It explicitly catalogs negative, null, and inconclusive results. Multiple split-mouth trials of adjunctive PBM in periodontal therapy failed to show statistically significant long-term differences in clinical attachment gain or microbiological profiles compared with scaling and root planing alone. In implant dentistry, several studies found no significant difference in final implant survival rates or secondary stability at 6 or 12 months after loading, even where early bone matrix deposition appeared slightly accelerated. In orthodontics, multiple well-controlled trials concluded that PBM did not clinically accelerate canine retraction or relieve initial alignment pain enough to justify daily intervention. The authors attribute these conflicting outcomes less to failures of photobiology in vitro and more to small sample sizes, publication bias, and uncalibrated delivery in which insufficient energy actually reached the target tissue.
Why does delivery matter so much? The review argues that a nominal wavelength, power setting, or fluence value does not define the biological exposure a tissue receives. Two devices both labeled as 810-nanometer systems may differ in laser versus LED emission, spectral bandwidth, beam divergence, spot size, pulse structure, thermal behavior, and field uniformity. The oral cavity compounds the problem: mucosal thickness and keratinization vary across sites, and saliva, blood, edema, pigmentation, bone, teeth, and restorative materials all modify photon propagation. Geometry is treated as a dose parameter in its own right, since a probe perpendicular to buccal mucosa does not create the same exposure as the same probe angled obliquely toward the posterior tongue. The authors also stress the biphasic response curve, in which insufficient energy produces no effect while excessive exposure can suppress or reverse the desired outcome, meaning the goal is the optimal biological window rather than the maximum tolerated dose.
To resolve these ambiguities, the review proposes distinguishing four levels of dosimetry: device output measured at the emitter, tissue-surface dose, target-tissue dose after attenuation, and the downstream biological dose. Reproducible protocols, it argues, require reporting at least 15 parameters spanning wavelength, spectral bandwidth, beam divergence, spot area, optical power, irradiance, emission mode, pulse frequency, duty cycle, exposure time, total energy, radiant exposure, source-to-tissue distance, contact mode, anatomical sites, session frequency, and cumulative sessions. Regular quality assurance should verify actual output rather than trusting displayed settings, particularly in multi-emitter devices where individual source degradation can create heterogeneous treatment fields.
The forward-looking portion of the review outlines a transition toward precision oral photomedicine. Computational photon-transport modeling, including Monte Carlo simulations adapted to stratified squamous epithelium, vascularized lamina propria, submucosal fat, muscle, and cortical bone, could predict volumetric energy deposition using wavelength-dependent absorption and scattering coefficients influenced by hemoglobin, water, and melanin concentrations. Rather than prescribing rigid surface energy densities, clinicians could calculate the optical power needed to reach a therapeutic threshold at deep targets such as minor salivary glands or alveolar ridges. Real-time optical monitoring, drawing on precedents like optical coherence tomography and diffuse reflectance spectroscopy in photodynamic oncology, could track microvascular blood flow, tissue oxygenation, and chairside salivary biomarkers such as interleukin-1 beta and tumor necrosis factor alpha. Artificial intelligence could then integrate patient phenotype, anatomical mapping, biomarker profiles, and device histories into closed-loop adjustments of power, pulse frequency, and duty cycle during treatment.
Safety receives detailed attention. The primary clinical hazard is accidental ocular exposure, making wavelength-specific protective eyewear mandatory for clinician, patient, and assistants. Although PBM is defined as nonthermal, multi-emitter LED arrays and high-power probes can generate localized surface heating, especially over pigmented tissues or metallic restorations, so irradiance must stay below thermal thresholds. Contraindications include direct application over active primary malignant lesions outside approved supportive protocols, active systemic lupus erythematosus lesions, and the gravid uterus, and patients must be screened for photosensitizing medications such as amiodarone, tetracyclines, and thiazides. In oncology specifically, the review notes that long-term clinical data from supportive-care PBM trials have shown no adverse oncological signals and that international organizations support its use in defined settings, while insisting that prospective registries document cancer types, irradiated fields, and long-term recurrence outcomes. Home-use devices introduce further risks, including unsupervised ocular exposure, thermal injury from prolonged single-spot application, and therapeutic failure from battery drift, prompting calls for integrated contact sensors, auto-shutoff timers, and clinician supervision.
The review frames the field’s evolution in four paradigms: device-centered PBM with fixed manufacturer settings, protocol-centered PBM with indication-specific surface parameters, anatomy-centered PBM with broad coverage arrays and attenuation modeling, and finally patient-centered precision oral photomedicine integrating real-time anatomy, dynamic tissue optics, biomarker monitoring, and adaptive AI dosimetry. Standardization, the authors argue, is the prerequisite for personalization rather than its opposite. The challenge of the coming decade, they conclude, is not the discovery of a single magic wavelength but the shift from emitted device output to dynamically verified target-tissue dose, supported by standardized reporting, independent calibration, dose-ranging trials, and multi-center safety registries.
Subject of Research: Photobiomodulation therapy and dosimetry challenges across oral health applications
Article Title: Biophotonics in oral health: bridging light-based innovation and clinical practice
Article References: Bensadoun, R. J., Lairedj, K., & Carlotti, B. R. (2026). Biophotonics in oral health: bridging light-based innovation and clinical practice. Frontiers in Oral Health, 7, 1978161. https://doi.org/10.3389/froh.2026.1978161
Image Credits: AI Generated
DOI: 10.3389/froh.2026.1978161
Keywords: photobiomodulation, oral health, oral mucositis, dosimetry, low-level laser therapy, dentistry, biophotonics, head and neck cancer, xerostomia, temporalomandibular disorders, laser safety, precision medicine
News Source: Ophelia Keating. (October 28, 2026). Light therapy in dentistry moves toward precision dosimetry, review argues. Scienmag.
